Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
SAN DIEGO, March 07, 2017 -- Retrophin, Inc. (Nasdaq:RTRX) today announced that Stephen Aselage, chief executive officer, will present at the Barclays Global Healthcare Conference in Miami on Wednesday, March 15, 2017 at 2:05 p.m. ET.
A live webcast of the presentation will be available at http://ir.retrophin.com/events.cfm and an archived replay will be accessible for at least 30 days.
About Retrophin
Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company’s approach centers on its pipeline featuring late-stage assets targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets in several rare diseases is also underway. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Thiola®, Cholbam® and Chenodal®.
Contact: Chris Cline, CFA Senior Director, Investor Relations 646-564-3680 [email protected]
